Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group ( (HK:2005) ) has issued an announcement.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Epinephrine Hydrochloride Injection, a critical drug for cardiopulmonary resuscitation and treatment of severe dyspnea and anaphylaxis. This development marks a significant step in the company’s product offerings, potentially enhancing its market position and providing stakeholders with an updated view of its business advancements.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in creating essential medical products, including drugs for cardiopulmonary resuscitation and treatments for severe dyspnea and anaphylaxis.
YTD Price Performance: -4.42%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.23B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.